Gene therapy for leukemia and lymphoma

Hematology/Oncology Clinics of North America

Volumn 12, Issue 3, 1998, Pages 631-648

  Adams, S W ^a   Emerson, S G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; GENE TARGETING; GENE THERAPY; HUMAN; LEUKEMIA; LYMPHOMA; PRIORITY JOURNAL; REVIEW; SUICIDE GENE;

EID: 0031848119     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70012-5     Document Type: Article

References (63)

1. J. Bartlett K. Quattrocchi R. Samulski The development of adeno-associated virus as a vector for cancer gene therapy Sobol R.E. Scanlon K.J. The Internet Book of Gene Therapy: Cancer Therapeutics 1995 Appleton & Lange Stamford. CT 27 39
2. M. Bishop J. Jackson S. Tarantolo Ex vivo treatment of bone marrow with phosphothioate oligonucleotide OL (1) p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome J Hematother 6 1997 441 446
3. C. Bonini G. Ferrari S. Verzeletti HSV-TK gene transfer into donor leukocytes for control of allogeneic graft-versus-leukemia Science 276 1997 1719 1724
4. M.K. Brenner Gene marking Hum Gene Ther 7 1996 1927 1936
5. M.K. Brenner J. Mirro C. Hurwitz Autologous bone marrow transplant for children with AML in first complete remission: Use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse Hum Gene Ther 2 1991 137 159
6. M.K. Brenner D.R. Rill R.C. Moen Gene-marking to trace the origin of relapse after autologous bone marrow transplantation Lancet 341 1993 85 86
7. M.K. Brenner R. Krance H.E. Heslop Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission Hum Gene Ther 5 1994 481 499
8. M.K. Brenner D.R. Rill M.S. Hollady Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients Lancet 342 1993 1134 1137
9. D.A. Brown S.H. Kang S.M. Gryaznov Effect of phosphothioate modification of oxydeoxynucleotides on specific protein bonding J Biol Chem 269 1994 26801 26805
10. B. Calabretta R. Sims M. Valtieri Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb oligodeoxynucleotides: An in vitro study relevant to bone marrow purging Proc Natl Acad Sci USA 88 1991 2351 2355
11. L. Chen S. Ashe W.A. Brady Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 Cell 71 1992 1093 1102
12. J. Cheng J.K. Yee J. Yeargin Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene Cancer Res 52 1992 222 226
13. J.S. Cohen Phosphothioate oligodeoxynucleotides Crooke S.T. Lebleu B. Antisense Research and Applications 1993 CRC Press Boca Raton FL 205
14. C.A. Corey A.D. Desilva C.A. Holland D.A. Williams Serial transplantation of methotrexate-resistant bone marrow: Protection of murine recipients from drug toxicity by progeny of transduced stem cells Blood 75 1990 337 343
15. K. Cornetta E.F. Srour A. Moore Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia Hum Gene Ther 7 1996 1323 1329
16. S.T. Crooke Advances in understanding the pharmacological properties of antisense oligonucleotides Adv Pharmacol 40 1997 1 41
17. D. Curiel Targeted tumor cytotoxicity mediated by intracellular single-chain anti-oncogene antibodies Adv Pharmacol 40 1997 51 83
18. A. Deisseroth Z. Zhifei D. Claxton Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML Blood 83 1994 3068 3076
19. Department of Health and Human Services National Institutes of Health Recombinant DNA Advisory Committee Regulatory Issues Hum Gene Ther 9 1998 420 445
20. D. Dilloo M. Brown M. Roskrow CD40 ligand induces antileukemia immune response in vivo Blood 90 1997 1927 1933
21. W. Doerfler The abortive infection and malignant transformation by adenoviruses: Integration of viral DNA and control of viral gene expression by specific patterns of DNA methylation Adv Virus Res 39 1991 89 128
22. E.R. Fearon D.R. Pardoll T. Itaya Interleukin-2 production by tumor cells bypasses T-helper function in generation of an antitumor response Cell 60 1990 397 403
23. G. Formi F. Cavallo M. Consalvo Molecular approaches to cancer immunotherapy Cytokine Mol Ther 1 1995 225 248
24. S. Frauhauf D.A. Breems S. Knaan-Shanzer Frequency analysis of multidrug resistance-1 gene transfer into human primitive hematopoietic progenitor cells using the cobblestone area forming assay and detection of vector-mediated P-glycoprotein expression by rhodamine-123 Hum Gene Ther 7 1996 1219 1231
25. A. Geller K. Keyomarsi J. Bryan A. Pardee An efficient deletion mutant packing system for defective herpes simplex viral vectors: Potential application to human gene therapy and neuronal physiology Proc Natl Acad Sci USA 87 1990 8950 8954
26. M.A. Guvakova L.A. Yakubov I. Vlodavsky Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix J Biol Chem 270 1995 2620 2627
27. E.G. Hanania S. Fu I. Roninson Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit Gene Ther 2 1995 279 284
28. E.G. Hanania Z. Fu Z. Zu Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene Gene Ther 2 1995 285 294
29. C.C. Harris Structure and function of the p53 tumor suppressor gene J Natl Cancer Inst 88 1996 1442 1455
30. N. Hirano T. Takahashi T. Takahashi Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells Hum Gene Ther 8 1997 1375 1384
31. A. Irie H. Kijima T. Ohkawa Anti-oncogene ribozymes for cancer therapy Adv Pharmacol 40 1997 207 257
32. R.J. Knox F. Friedlos M.P. Boland The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT) Cancer Metastasis Rev 12 1993 195 212
33. S.M. Kornblau H.J. Xu del Giglio A. Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia Cancer Res 52 1992 4587 4590
34. W. Lange M. Daskalakis J. Finke G. Dolken Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs FEBS Lett 388 1994 175 178
35. L. Leopold S. Shore T. Newkirk Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias Blood 85 1995 2162 2170
36. S. Letourneau M. Greenbaum D. Cournoyer Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoietic progenitor cells Hum Gene Ther 7 1996 831 840
37. H. Matsushita H. Kobayashi S. Mori Ribozymes cleave the AML1/MTG8 fusion transcript and inhibit proliferation of leukemic cells with t(8;21) Biochem Biophys Res Commun 215 1995 431 437
38. U.A. Matulonis C. Dosiou C. Lamont Role of B7 in mediating an immune response to myeloid leukemia cells Blood 85 1995 2507 2515
39. M. McCall P. Hendry P.A. Jennings Minimal sequence requirements for ribozyme activity Proc Natl Acad Sci USA 89 1992 5710 5714
40. S. Meyers N. Lenny S. Hiebert The t (8; 21) fusion protein interferes with AML-1B–dependent transcriptional activation Mol Cell Biol 15 1995 1974 1982
41. A. Miller D. Miller J. Garcia C. Lynch Use of retroviral vectors for gene transfer and expression Wu R. Methods in Enzymology 127 1993 Academic Press San Diego 581 599
42. B. Moss C. Flexner Vaccina virus expression vectors Annu Rev Immunol 5 1987 305 324
43. K. Murata M. Fujita Y. Yamada In vivo retrovirus-mediated herpes simplex virus thymidine kinase gene therapy approach for adult T cell leukemia in a rat model Jpn J Cancer Res 88 1997 492 500
44. G. Parmiani M.P. Colombo C. Melani F. Arienti Cytokine gene transduction in the immunotherapy of cancer Adv Pharmacol 40 1997 259 307
45. M. Ratajczak J. Kant S. Luger In vivo treatment of human leukemia in a SCID mouse model with c-myb antisense oligodexynucleotides Proc Natl Acad USA 89 1992 11823 11827
46. D. Ronen D. Schwartz Y. Teitz Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels Cell Growth Differ 7 1996 21 30
47. I.B. Roninson The role of MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo Biochem Pharmacol 43 1992 95 102
48. J. Rubnitz A. Look Molecular genetics of childhood leukemias J Pediatr Hematol Oncol 20 1998 1 11
49. L. Santodonato M. Ferrantini L. Gabriele Cure of mice with established Friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-a1 and herpes simplex thymidine kinase followed by ganciclovir Hum Gene Ther 7 1996 1 10
50. T. Skorski M. Nieborowska-Skorska K. Campbell Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes J Exp Med 182 1995 1645 1653
51. T. Skorski M. Nieborowska-Skorska N. Nicolaides Suppression of Philadelphia leukemia cell growth in mice by BCR-ABL antisense oligonucleotide Proc Natl Acad Sci USA 91 1994 4504 4508
52. T. Skorski D. Perrotti M. Nieborowska-Skorska Antileukemia effect of c-myc N3′-P5′ phosphoramidate antisense oligonucleotides in vivo Proc Natl Acad Sci USA 94 1997 3966 3971
53. D. Snyder Y. Wu J. Wang Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line Blood 82 1993 200
54. C.A. Stein Does antisense exist? Nat Med 1 1995 1119 1121
55. K. Takenaga M. Tagawa S. Sakiyama Therapeutic potency of transduction with herpes simplex virus thymidine kinase gene against multidrug resistant mouse leukemia cells Anticancer Res 16 1996 681 686
56. M. Ward C. Richardson P. Pioli Transfer and expression of the human multidrug resistance gene in human CD34+ cells Blood 84 1994 1408 1414
57. A. Webb D. Cunningham F. Cotter BCL-2 antisense therapy in patients with non-Hodgkin lymphoma Lancet 349 1997 1137 1141
58. M.X. Wei T. Tamiya M. Chase Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450-2B1 gene Hum Gene Ther 5 1994 969 978
59. R.A. Weinberg The retinoblastoma protein and cell cycle control Cell 81 1995 323 330
60. M. Weitzman J. Wilson S. Eck Adenovirus vectors in cancer gene therapy Sobol R.E. Scanlon K.J. The Internet Book of Gene Therapy: Cancer Therapeutics 1995 Appleton & Lange Stamford, CT 17 25
61. K.N. Wills D.C. Maneval M.P. Harris Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer Hum Gene Ther 5 1994 1079 1088
62. J.M. Wroblewski L.T. Lay Van Zant G. Selective elimination (purging) of contaminating malignant cells from hematopoietic stem cell autografts using recombinant adenovirus Cancer Gene Ther 3 1996 257 264
63. Xu H.-J. Strategies for approaching retinoblastoma tumor suppressor gene therapy Adv Pharmacol 40 1997 369 397